Adding liraglutide to standard treatment for 12 weeks significantly improved blood sugar, blood pressure, BMI, waist-hip ratio, lipid profiles, and inflammatory markers in 60 patients with abdominal obesity and type 2 diabetes.
Multi-target improvementLiraglutide improved glycolipid metabolism AND microinflammatory markers in abdominally obese T2D patients beyond what metformin alone achieved
What the researchers found
Liraglutide added to metformin significantly improved SBP, DBP, BMI, waist-hip ratio, glycolipid metabolism indices, and microinflammatory markers compared to metformin alone over 12 weeks (P<0.05). High medication safety reported.
Why it matters
Abdominal obesity with diabetes creates a particularly dangerous metabolic profile. Showing that liraglutide improves not just blood sugar but also inflammation — a key driver of cardiovascular risk — supports using GLP-1 peptide drugs for their broader metabolic benefits.
The numbers in context
60 patients, 30 per group. October 2020 to December 2021 at Jiande Hospital of Traditional Chinese Medicine.
How the study worked
Randomized controlled trial at a single Chinese hospital (Oct 2020-Dec 2021). 60 patients with abdominal obesity and T2D randomized to control (metformin 1g BID + lifestyle, n=30) or liraglutide group (metformin + liraglutide escalated to 1.8 mg/day, n=30) for 12 weeks.
Who was studied
Patients with abdominal obesity and T2DM
What this study cannot tell us
Small sample (30 per group). Single-center in China. 12 weeks may not capture long-term effects. Specific P-values and effect sizes for individual markers not provided in abstract. Open-label design may introduce bias.
How to read the evidence
Rated moderate: RCT design, but limited by small sample (n=60), single center, and likely open-label design.
When this study was published
Published in 2024. Conducted 2020-2021.
The bigger picture
This study adds to the evidence that GLP-1 peptide agonists address multiple aspects of metabolic disease simultaneously — not just blood sugar, but inflammation, lipids, and body composition — supporting their role as comprehensive metabolic therapies.
Questions still open
- Do the anti-inflammatory effects persist long-term, and do they translate to reduced cardiovascular events?
- How does liraglutide's anti-inflammatory effect compare to semaglutide or tirzepatide?
- Are the metabolic improvements maintained after liraglutide is discontinued?
Common questions
Does liraglutide reduce inflammation in diabetic patients?
Can liraglutide help with belly fat in diabetes?
Read the original research
Effects of GLP-1 Receptor Agonist on Glycolipid Metabolism and Micro Inflammatory Status in Patients with Abdominal Obesity and Type 2 Diabetes.
Alternative therapies in health and medicine
Citation
Shao, Wei; Wu, Jianli; Zhu, Meiqin; Wang, Yanqi; Ci, Haideng. (2024). Effects of GLP-1 Receptor Agonist on Glycolipid Metabolism and Micro Inflammatory Status in Patients with Abdominal Obesity and Type 2 Diabetes.. Alternative therapies in health and medicine.